U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7BrN4O2
Molecular Weight 259.0599
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMOTHEOPHYLLINE

SMILES

Cn1c2c(c(=O)n(C)c1=O)nc(Br)[nH]2

InChI

InChIKey=SKTFQHRVFFOHTQ-UHFFFAOYSA-N
InChI=1S/C7H7BrN4O2/c1-11-4-3(9-6(8)10-4)5(13)12(2)7(11)14/h1-2H3,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C7H7BrN4O2
Molecular Weight 259.0599
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Pamabrom is a diuretic drug, available in over-the-counter medications. The active diuretic ingredient in pamabrom is 8-bromotheophylline. It is used for the relief of temporary water weight gain; bloating; swelling; full feeling associated with the premenstrual and menstrual periods.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.2 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
DIUREX

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3685.6 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ACETAMINOPHEN
BROMOTHEOPHYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
46210.49 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ACETAMINOPHEN
BROMOTHEOPHYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
21.35 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered: ACETAMINOPHEN
BROMOTHEOPHYLLINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
25 mg 1 times / day multiple, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Fixed drug eruption...
AEs leading to
discontinuation/dose reduction:
Fixed drug eruption
Sources:
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 1
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 1
Sources:
Disc. AE: Diarrhea...
AEs leading to
discontinuation/dose reduction:
Diarrhea (mild, 1 patient)
Sources:
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (severe, 4 patients)
Vomiting (severe, 4 patients)
Skin rash (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Fixed drug eruption Disc. AE
25 mg 1 times / day multiple, oral
Dose: 25 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 26 years
n = 1
Health Status: unhealthy
Age Group: 26 years
Sex: F
Population Size: 1
Sources:
Diarrhea mild, 1 patient
Disc. AE
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 1
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 1
Sources:
Skin rash 1 patient
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Nausea severe, 4 patients
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Vomiting severe, 4 patients
Disc. AE
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Co-administed with::
2-amino-2-methyl-1-propanol
Sources:
unhealthy, 44-78 years
n = 18
Health Status: unhealthy
Condition: cardiac failure
Age Group: 44-78 years
Sex: M+F
Population Size: 18
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
A study of diuretic action of pamabrom (2-amino-2-methyl-propanol-1-8-bromotheophylline) in cardiac failure.
1953 Aug
Fixed drug eruption caused by pamabrom.
2009 Oct
Erythema multiforme secondary to dimenhydrinate in a patient with previous similar reactions to pamabrom.
2014 Mar
Patents

Patents

Sample Use Guides

Adults:  Take one (1) capsule after breakfast with a full glass of water.  Dose may be repeated after six (6) hours, not to exceed four (4) capsules per day. Start taking 5 or 6 days before onset of period and continue until desired relief is obtained or end of period. Drink 6 to 8 glasses of water daily.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Jun 26 03:21:06 UTC 2021
Edited
by admin
on Sat Jun 26 03:21:06 UTC 2021
Record UNII
FZG87K1MQ6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BROMOTHEOPHYLLINE
Systematic Name English
8-BROMOTHEOPHYLLINE [USP-RS]
Common Name English
NSC-164940
Code English
8-BROMOTHEOPHYLLINE
USP-RS  
Systematic Name English
1H-PURINE-2,6-DIONE, 8-BROMO-3,9-DIHYDRO-1,3-DIMETHYL-
Systematic Name English
Code System Code Type Description
FDA UNII
FZG87K1MQ6
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY
PUBCHEM
11808
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY
RXCUI
1546386
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY RxNorm
CAS
10381-75-6
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY
ECHA (EC/EINECS)
233-846-6
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY
EPA CompTox
10381-75-6
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY
DRUG BANK
DB14018
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY
USP_CATALOG
1077708
Created by admin on Sat Jun 26 03:21:06 UTC 2021 , Edited by admin on Sat Jun 26 03:21:06 UTC 2021
PRIMARY USP-RS
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY